{"nctId":"NCT00317239","briefTitle":"VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","startDateStruct":{"date":"2005-05"},"conditions":["Anemia"],"count":255,"armGroups":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL","interventionNames":["Drug: Ferric Carboxymaltose (FCM)"]},{"label":"Ferrous Sulfate tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ferrous Sulfate tablets"]}],"interventions":[{"name":"Ferrous Sulfate tablets","otherNames":[]},{"name":"Ferric Carboxymaltose (FCM)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females \\> or = 12 years of age\n* NDD-CKD subjects\n* Baseline hemoglobin \\< or = 11g/dl\n* Stable erythropoietin (EPO) status\n\nExclusion Criteria:\n\n* Known hypersensitivity to ferrous sulfate or IV iron\n* Unstable EPO status\n* Anemia not related to CKD\n* Chronic, serious infection\n* Recent IV iron\n* Recent blood transfusion\n* Recent blood loss\n* Need for surgery\n* Received investigational drug within 30 days\n* Female subjects who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Achieving an Increase in Hemoglobin â‰¥1g/dL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":147},"commonTop":["Constipation","Odema peripheral"]}}}